Aprocitentan 25 mg

DRUG4 trials

Sponsors

Idorsia Pharmaceuticals Ltd.

Conditions

Essential HypertensionHealthy SubjectsHypertensionRenal Insufficiency, ChronicResistant Hypertension

Phase 1

To Study the Effect of Aprocitentan on the Electrical Activity of the Heart in Healthy Men and Women

CompletedNCT04281342

Idorsia Pharmaceuticals Ltd.Healthy Subjects

Start: 2020-01-14End: 2021-09-03Updated: 2022-11-23

Phase 2

Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension

CompletedNCT02603809

Idorsia Pharmaceuticals Ltd.Essential Hypertension

Start: 2015-12-14End: 2017-04-07Updated: 2022-11-23

Phase 3

A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety

CompletedNCT03541174

Idorsia Pharmaceuticals Ltd.Resistant Hypertension

Start: 2018-06-18End: 2022-04-25Updated: 2023-03-21

A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease.

WithdrawnNCT04162366

Idorsia Pharmaceuticals Ltd.Hypertension, Renal Insufficiency, Chronic

Start: 2020-01-31End: 2021-07-15Updated: 2022-11-23

Related Papers

Aprocitentan in Patients With Chronic Kidney Disease and Resistant Hypertension.

2025-12-09

Aprocitentan for Blood Pressure Reduction in Black Patients

Hypertension2025-01-227 citations

Abstract P437: Correlation between plasma CT-proET-1 and renal dysfunction in patients with resistant hypertension. A biomarker analysis of the PRECISION study.

Hypertension2024-09-01

Abstract 19: Effect of the endothelin receptor antagonist aprocitentan on plasma endothelin, renin and aldosterone concentrations in patients with resistant hypertension. A biomarker analysis of the PRECISION study.

Hypertension2024-09-01

Aprocitentan, a dual endothelin-1 (ET-1) antagonist for treating resistant hypertension: Mechanism of action and therapeutic potential.

2023-09-2211 citations

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment

Scientific Reports2022-11-0917 citations

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.

2022-11-07143 citations

Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension.

2021-07-1216 citations

Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension

Hypertension2020-02-1786 citations

34Efficacy and safety of various doses of the new dual endothelin receptor antagonist aprocitentan in the treatment of hypertension

European Heart Journal2019-10-012 citations